-$0.58 Earnings Per Share Expected for Aileron Therapeutics Inc (ALRN) This Quarter

Brokerages forecast that Aileron Therapeutics Inc (NASDAQ:ALRN) will announce ($0.58) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Aileron Therapeutics’ earnings, with estimates ranging from ($0.65) to ($0.49). Aileron Therapeutics reported earnings of ($0.43) per share in the same quarter last year, which suggests a negative year over year growth rate of 34.9%. The firm is scheduled to announce its next earnings report on Thursday, November 8th.

On average, analysts expect that Aileron Therapeutics will report full year earnings of ($2.42) per share for the current financial year, with EPS estimates ranging from ($2.47) to ($2.37). For the next year, analysts expect that the business will report earnings of ($2.15) per share, with EPS estimates ranging from ($2.71) to ($1.63). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Aileron Therapeutics.

Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.04).

A number of research firms recently issued reports on ALRN. ValuEngine downgraded shares of Aileron Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, June 29th. Zacks Investment Research downgraded shares of Aileron Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th.

In other Aileron Therapeutics news, major shareholder Bioventures Ltd Novartis sold 8,458 shares of the stock in a transaction that occurred on Monday, July 30th. The shares were sold at an average price of $3.35, for a total value of $28,334.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 129,798 shares of company stock valued at $409,889 in the last ninety days. 16.10% of the stock is owned by corporate insiders.

A hedge fund recently raised its stake in Aileron Therapeutics stock. Millennium Management LLC raised its position in Aileron Therapeutics Inc (NASDAQ:ALRN) by 565.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 123,658 shares of the company’s stock after acquiring an additional 105,073 shares during the quarter. Millennium Management LLC owned 0.84% of Aileron Therapeutics worth $670,000 at the end of the most recent quarter. 5.94% of the stock is currently owned by institutional investors and hedge funds.

ALRN traded down $0.01 on Friday, reaching $2.38. 87 shares of the company’s stock were exchanged, compared to its average volume of 72,120. The company has a market cap of $37.73 million, a PE ratio of -1.38 and a beta of -0.64. Aileron Therapeutics has a twelve month low of $1.98 and a twelve month high of $14.15. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.85 and a current ratio of 5.85.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Read More: Understanding Relative Strength Index

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply